Influence of Multidrug Resistance on Tuberculosis Treatment Outcomes with Standardized Regimens
- 1 August 2008
- journal article
- research article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 178 (3), 306-312
- https://doi.org/10.1164/rccm.200802-240oc
Abstract
Rationale: Multidrug-resistant tuberculosis (TB) poses a major challenge to global TB control. We analyzed the association between estimated prevalence of initial or acquired MDR-TB, and treatment outcomes reported nationally. Objectives: We analyzed the estimated prevalence of initial or acquired MDR-TB and treatment outcomes reported nationally. Methods: Countries were analyzed if multidrug resistance prevalence estimates were available, and if they reported outcomes for more than 250 cases treated using standardized regimens in 2003 and/or 2004. Data sources were the World Health Organization for treatment regimens, prevalence of initial multidrug resistance, and reported cases and treatment outcomes in 2003 and 2004; the Joint United Nations Programme on HIV/AIDS for HIV seroprevalence; and the World Bank for income per capita. The adjusted impact of initial multidrug resistance on initial and retreatment outcomes was estimated with weighted multivariate linear regression. Measurements and Main Results: Among countries using one of two standardized initial regimens, failure rates averaged 5.0%, and relapse rates averaged 12.8% in the 20 countries where prevalence of initial multidrug resistance exceeded 3%, compared with an average of 1.6% (P < 0.0001) and 8.1% (P = 0.0002), respectively, in 83 countries where initial multidrug resistance prevalence was less than 3%. In 92 countries using one standardized retreatment regimen, failure rates were 2.7%, 3.8%, 6.2%, and 8.1% in quartiles of increasing prevalence of acquired multidrug resistance (P < 0.0001). When stratified by initial multidrug resistance prevalence, initial and retreatment outcomes in the 79 countries using the 6-month rifampin initial regimen were not significantly different from the 24 countries using the 2-month rifampin initial regimen. Conclusions: Currently recommended standardized TB initial and retreatment regimens should be reevaluated in countries where prevalence of initial multidrug resistance exceeds 3%, in view of poor treatment outcomes.Keywords
This publication has 12 references indexed in Scilit:
- Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysisThe Lancet, 2006
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Global Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2006
- Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trialThe Lancet, 2004
- Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant TuberculosisScience, 2002
- Responding to Market Failures in Tuberculosis ControlScience, 2001
- Standard Short-Course Chemotherapy for Drug-Resistant TuberculosisPublished by American Medical Association (AMA) ,2000
- Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 MonthsAmerican Review of Respiratory Disease, 1991
- Controlled Clinical Trial of Levamisole in Short-course Chemotherapy for Pulmonary Tuberculosis: A Kenyan/Zambian/British Medical Research Council Collaborative StudyAmerican Review of Respiratory Disease, 1989
- Controlled trial of 4 three-times-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis second report: the results up to 24 monthsTubercle, 1982